- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01269905
Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management
January 3, 2011 updated by: Johann Wolfgang Goethe University Hospital
The optimal valve substitute for patients between 60-70 years is controversial.
We compared anticoagulation-related adverse events (ARAE) in patients receiving mechanical heart valve replacement (MHVR) on INR self-management vs. stentless bioprosthesis, to assess whether the risk of structural valve deterioration (SVD) is still out-weighted by the benefit of not requiring permanent anticoagulation.
Study Overview
Status
Completed
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients received heart valve replacement and were retrospectively allocated in three groups
Description
Inclusion Criteria:
- heart valve replacement
Exclusion Criteria:
- CABG
- Afib
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
---|
Group A
Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
|
Group B
Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
|
Group C
Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
January 3, 2011
First Submitted That Met QC Criteria
January 3, 2011
First Posted (Estimate)
January 4, 2011
Study Record Updates
Last Update Posted (Estimate)
January 4, 2011
Last Update Submitted That Met QC Criteria
January 3, 2011
Last Verified
January 1, 2005
More Information
Terms related to this study
Other Study ID Numbers
- COAG-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anticoagulation
-
Brigham and Women's HospitalCSL BehringRecruitingAnticoagulation | Anticoagulation ReversalUnited States
-
Bristol-Myers SquibbPfizerCompleted
-
Bristol-Myers SquibbBadalona Serveis Assistencials; IMS HealthCompleted
-
University of TurkuUnknown
-
Goethe UniversityUnknown
-
William S. Middleton Memorial Veterans HospitalUniversity of Wisconsin, MadisonCompleted
-
University of Medicine and Pharmacy at Ho Chi Minh...Unknown
-
University of AlbertaCompleted
-
BayerJanssen Research & Development, LLC; RTI Health SolutionsCompletedAnticoagulationGermany, United Kingdom, France, Spain
-
Aalborg University HospitalCompletedAnticoagulation